Kristina Drott has left the board of the research company Respiratorius for health reasons. According to CEO Johan Drott, through her research and the founding of Valcuria, she has been an important prerequisite for the company's progress with the drug candidate VAL001. "The board supports her decision and hopes for a speedy recovery and a future return to board work," he says. After the resignation, the board consists of three members and remains quorate in accordance with the articles of association.